Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 plus anti-PD-1/L1 antibody and platinum-etoposide chemotherapy in first-line extensive-stage small cell lung cancer
CTR20232950Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in small cell lung cancer (SCLC), sponsored by InnoCare Pharma. Started Nov 2023; status: active.
02
Drugs
ifebemtinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20232950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232950.